Outcomes of UCB transplantation are comparable in FLT3+ AML: Results of CIBMTR, EUROCORD and EBMT collaborative analysis

C. Ustun; F. Giannotti; M. J. Zhang; H. L. Wang; C. Brunstein; M. Labopin; V. Rocha; M. De Lima; F. Baron; B. M. Sandmaier; M. Eapen; E. Gluckman; A. Nagler; D. J. Weisdorf; A. Ruggeri

doi:10.1038/leu.2017.42

Outcomes of UCB transplantation are comparable in FLT3+ AML: Results of CIBMTR, EUROCORD and EBMT collaborative analysis

C. Ustun, F. Giannotti, M. J. Zhang, H. L. Wang, C. Brunstein, M. Labopin, V. Rocha, M. De Lima, F. Baron, B. M. Sandmaier, M. Eapen, E. Gluckman, A. Nagler, D. J. Weisdorf, A. Ruggeri

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may improve leukemia-free survival (LFS) in FMS-like tyrosine kinase 3+ (FLT3+) acute myeloid leukemia (AML), which has poor prognosis because of high relapse rates. Umbilical cord blood (UCB) HCT outcomes are largely unknown in this population. We found that compared with sibling HCT, relapse risks were similar after UCB (n=126) (hazard ratio (HR) 0.86, P=0.54) and URD (n=91) (HR 0.81, P=0.43). UCB HCT was associated with statistically higher non-relapse mortality compared with sibling HCT (HR 2.32, P=0.02), but not vs URD (HR 1.72, P=0.07). All three cohorts had statistically nonsignificant 3-year LFS: 39% (95% confidence interval (CI): 30-47) after UCB, 43% (95% CI: 30-54) after sibling and 50% (95% CI: 40-60) after URD. Chronic graft-versus-host disease rates were significantly lower after UCB compared with either sibling (HR 0.59, P=0.03) or URD (HR 0.49, P=0.001). Adverse factors for LFS included high leukocyte count at diagnosis and HCT during CR2 (second CR). UCB is a suitable option for adults with FLT3+ AML in the absence of an human leukocyte antigen-matched sibling and its immediate availability may be particularly important for FLT3+ AML where early relapse is common, thus allowing HCT in CR1 (first CR) when outcomes are best.

Original language	English (US)
Pages (from-to)	1408-1414
Number of pages	7
Journal	Leukemia
Volume	31
Issue number	6
DOIs	https://doi.org/10.1038/leu.2017.42
State	Published - Jun 1 2017

Access

10.1038/leu.2017.42

Fingerprint Dive into the research topics of 'Outcomes of UCB transplantation are comparable in FLT3+ AML: Results of CIBMTR, EUROCORD and EBMT collaborative analysis'. Together they form a unique fingerprint.

Cite this

Ustun, C., Giannotti, F., Zhang, M. J., Wang, H. L., Brunstein, C., Labopin, M., Rocha, V., De Lima, M., Baron, F., Sandmaier, B. M., Eapen, M., Gluckman, E., Nagler, A., Weisdorf, D. J., & Ruggeri, A. (2017). Outcomes of UCB transplantation are comparable in FLT3+ AML: Results of CIBMTR, EUROCORD and EBMT collaborative analysis. Leukemia, 31(6), 1408-1414. https://doi.org/10.1038/leu.2017.42

Outcomes of UCB transplantation are comparable in FLT3+ AML : Results of CIBMTR, EUROCORD and EBMT collaborative analysis. / Ustun, C.; Giannotti, F.; Zhang, M. J.; Wang, H. L.; Brunstein, C.; Labopin, M.; Rocha, V.; De Lima, M.; Baron, F.; Sandmaier, B. M.; Eapen, M.; Gluckman, E.; Nagler, A.; Weisdorf, D. J.; Ruggeri, A.

In: Leukemia, Vol. 31, No. 6, 01.06.2017, p. 1408-1414.

Research output: Contribution to journal › Article › peer-review

Ustun, C, Giannotti, F, Zhang, MJ, Wang, HL, Brunstein, C, Labopin, M, Rocha, V, De Lima, M, Baron, F, Sandmaier, BM, Eapen, M, Gluckman, E, Nagler, A, Weisdorf, DJ & Ruggeri, A 2017, 'Outcomes of UCB transplantation are comparable in FLT3+ AML: Results of CIBMTR, EUROCORD and EBMT collaborative analysis', Leukemia, vol. 31, no. 6, pp. 1408-1414. https://doi.org/10.1038/leu.2017.42

Ustun, C. ; Giannotti, F. ; Zhang, M. J. ; Wang, H. L. ; Brunstein, C. ; Labopin, M. ; Rocha, V. ; De Lima, M. ; Baron, F. ; Sandmaier, B. M. ; Eapen, M. ; Gluckman, E. ; Nagler, A. ; Weisdorf, D. J. ; Ruggeri, A. / Outcomes of UCB transplantation are comparable in FLT3+ AML : Results of CIBMTR, EUROCORD and EBMT collaborative analysis. In: Leukemia. 2017 ; Vol. 31, No. 6. pp. 1408-1414.

@article{c59fa0c02cb84bf589298ac61a2f6cf0,

title = "Outcomes of UCB transplantation are comparable in FLT3+ AML: Results of CIBMTR, EUROCORD and EBMT collaborative analysis",

abstract = "Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may improve leukemia-free survival (LFS) in FMS-like tyrosine kinase 3+ (FLT3+) acute myeloid leukemia (AML), which has poor prognosis because of high relapse rates. Umbilical cord blood (UCB) HCT outcomes are largely unknown in this population. We found that compared with sibling HCT, relapse risks were similar after UCB (n=126) (hazard ratio (HR) 0.86, P=0.54) and URD (n=91) (HR 0.81, P=0.43). UCB HCT was associated with statistically higher non-relapse mortality compared with sibling HCT (HR 2.32, P=0.02), but not vs URD (HR 1.72, P=0.07). All three cohorts had statistically nonsignificant 3-year LFS: 39% (95% confidence interval (CI): 30-47) after UCB, 43% (95% CI: 30-54) after sibling and 50% (95% CI: 40-60) after URD. Chronic graft-versus-host disease rates were significantly lower after UCB compared with either sibling (HR 0.59, P=0.03) or URD (HR 0.49, P=0.001). Adverse factors for LFS included high leukocyte count at diagnosis and HCT during CR2 (second CR). UCB is a suitable option for adults with FLT3+ AML in the absence of an human leukocyte antigen-matched sibling and its immediate availability may be particularly important for FLT3+ AML where early relapse is common, thus allowing HCT in CR1 (first CR) when outcomes are best.",

author = "C. Ustun and F. Giannotti and Zhang, {M. J.} and Wang, {H. L.} and C. Brunstein and M. Labopin and V. Rocha and {De Lima}, M. and F. Baron and Sandmaier, {B. M.} and M. Eapen and E. Gluckman and A. Nagler and Weisdorf, {D. J.} and A. Ruggeri",

year = "2017",

month = jun,

day = "1",

doi = "10.1038/leu.2017.42",

language = "English (US)",

volume = "31",

pages = "1408--1414",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Outcomes of UCB transplantation are comparable in FLT3+ AML

T2 - Results of CIBMTR, EUROCORD and EBMT collaborative analysis

AU - Ustun, C.

AU - Giannotti, F.

AU - Zhang, M. J.

AU - Wang, H. L.

AU - Brunstein, C.

AU - Labopin, M.

AU - Rocha, V.

AU - De Lima, M.

AU - Baron, F.

AU - Sandmaier, B. M.

AU - Eapen, M.

AU - Gluckman, E.

AU - Nagler, A.

AU - Weisdorf, D. J.

AU - Ruggeri, A.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may improve leukemia-free survival (LFS) in FMS-like tyrosine kinase 3+ (FLT3+) acute myeloid leukemia (AML), which has poor prognosis because of high relapse rates. Umbilical cord blood (UCB) HCT outcomes are largely unknown in this population. We found that compared with sibling HCT, relapse risks were similar after UCB (n=126) (hazard ratio (HR) 0.86, P=0.54) and URD (n=91) (HR 0.81, P=0.43). UCB HCT was associated with statistically higher non-relapse mortality compared with sibling HCT (HR 2.32, P=0.02), but not vs URD (HR 1.72, P=0.07). All three cohorts had statistically nonsignificant 3-year LFS: 39% (95% confidence interval (CI): 30-47) after UCB, 43% (95% CI: 30-54) after sibling and 50% (95% CI: 40-60) after URD. Chronic graft-versus-host disease rates were significantly lower after UCB compared with either sibling (HR 0.59, P=0.03) or URD (HR 0.49, P=0.001). Adverse factors for LFS included high leukocyte count at diagnosis and HCT during CR2 (second CR). UCB is a suitable option for adults with FLT3+ AML in the absence of an human leukocyte antigen-matched sibling and its immediate availability may be particularly important for FLT3+ AML where early relapse is common, thus allowing HCT in CR1 (first CR) when outcomes are best.

AB - Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may improve leukemia-free survival (LFS) in FMS-like tyrosine kinase 3+ (FLT3+) acute myeloid leukemia (AML), which has poor prognosis because of high relapse rates. Umbilical cord blood (UCB) HCT outcomes are largely unknown in this population. We found that compared with sibling HCT, relapse risks were similar after UCB (n=126) (hazard ratio (HR) 0.86, P=0.54) and URD (n=91) (HR 0.81, P=0.43). UCB HCT was associated with statistically higher non-relapse mortality compared with sibling HCT (HR 2.32, P=0.02), but not vs URD (HR 1.72, P=0.07). All three cohorts had statistically nonsignificant 3-year LFS: 39% (95% confidence interval (CI): 30-47) after UCB, 43% (95% CI: 30-54) after sibling and 50% (95% CI: 40-60) after URD. Chronic graft-versus-host disease rates were significantly lower after UCB compared with either sibling (HR 0.59, P=0.03) or URD (HR 0.49, P=0.001). Adverse factors for LFS included high leukocyte count at diagnosis and HCT during CR2 (second CR). UCB is a suitable option for adults with FLT3+ AML in the absence of an human leukocyte antigen-matched sibling and its immediate availability may be particularly important for FLT3+ AML where early relapse is common, thus allowing HCT in CR1 (first CR) when outcomes are best.

UR - http://www.scopus.com/inward/record.url?scp=85012303056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012303056&partnerID=8YFLogxK

U2 - 10.1038/leu.2017.42

DO - 10.1038/leu.2017.42

M3 - Article

C2 - 28119528

AN - SCOPUS:85012303056

VL - 31

SP - 1408

EP - 1414

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -